Petros Pharmaceuticals, Inc. (PTPI)

Every figure this model derived for PTPI, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2024-12-31.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 24,587 PaymentsToAcquirePropertyPlantAndEquipment 2024-12-31
cash 3,488,595 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 3,545,719 AssetsCurrent 2026-06-30
current liabilities 2,844,825 LiabilitiesCurrent 2026-06-30
equity 700,894 StockholdersEquity 2026-06-30
interest expense 560,909 InterestExpenseDebt 2024-12-31
revenue 5,112,046 RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31
sbc 304,634 ShareBasedCompensation 2025-12-31

The ratios

The figures themselves rather than their scores — what somebody looking up PTPI on one particular measure came for.

RatioValue
current ratio1.25
current ratio reported1.25
dilution pct8668.77
revenue growth-26.81
revenue growth per share-99.17
sbc pct revenue5.96

What to be careful about

What this model itself distrusts about PTPI's figures. Written by the derivation as it ran, not added afterwards.